SCP
ABBV icon

Shorepoint Capital Partners’s AbbVie ABBV Stock Holding History

Shorepoint Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$7.46M Buy
+32,205
New +$6.56M 1.48% 19
2025
Q1 		$6.97M Sell
33,266
-1,614
-5% -$314K 1.58% 16
2024
Q4 		$6.2M Sell
34,880
-256
-0.7% -$47.1K 1.42% 22
2024
Q3 		$6.94M Sell
35,136
-1,941
-5% -$362K 1.58% 21
2024
Q2 		$6.36M Sell
37,077
-53
-0.1% -$8.78K 1.49% 21
2024
Q1 		$6.76M Sell
37,130
-2,319
-6% -$400K 1.65% 16
2023
Q4 		$6.11M Sell
39,449
-6,982
-15% -$1.02M 1.64% 16
2023
Q3 		$6.92M Sell
46,431
-3,341
-7% -$490K 2.03% 14
2023
Q2 		$6.71M Sell
49,772
-3,508
-7% -$514K 1.89% 16
2023
Q1 		$8.49M Sell
53,280
-7,310
-12% -$1.12M 2.43% 6
2022
Q4 		$9.79M Buy
60,590
+11,608
+24% +$1.78M 2.72% 4
2022
Q3 		$6.57M Buy
48,982
+725
+2% +$104K 3.14% 4
2022
Q2 		$7.39M Sell
48,257
-3,569
-7% -$545K 3.12% 3
2022
Q1 		$8.4M Sell
51,826
-3,969
-7% -$577K 3.51% 3
2021
Q4 		$7.55M Buy
55,795
+485
+0.9% +$57.3K 3.07% 6
2021
Q3 		$5.97M Buy
+55,310
New +$6.32M 2.68% 8
2021
Q1 		$5.28M Sell
48,743
-27,620
-36% -$2.95M 2.82% 5
2020
Q4 		$8.18M Buy
76,363
+138
+0.2% +$13.3K 4.54% 2
2020
Q3 		$6.68M Sell
76,225
-2,858
-4% -$269K 4.15% 3
2020
Q2 		$7.76M Sell
79,083
-11,064
-12% -$974K 5.06% 2
2020
Q1 		$6.87M Sell
90,147
-4,897
-5% -$417K 5.51% 2
2019
Q4 		$8.41M Sell
95,044
-1,155
-1% -$95.9K 4.81% 1
2019
Q3 		$7.28M Buy
96,199
+2,983
+3% +$205K 4.3% 3
2019
Q2 		$6.78M Buy
93,216
+6,123
+7% +$481K 3.87% 3
2019
Q1 		$7.02M Buy
+87,093
New +$7.12M 3.97% 3

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Shorepoint Capital Partners's ABBV Position: Q3 2025 in Review

Shorepoint Capital Partners opened a new position in AbbVie (ABBV) in Q3 2025: 32,205 shares worth $7.46M. The stake represents 1.48% of the portfolio and ranks #19 among its holdings. This is a return to the name: Shorepoint Capital Partners previously reported a position in ABBV as recently as Q1 2025.

Shorepoint Capital Partners first reported a position in ABBV in Q1 2019 and has held it in 25 quarters since. The position peaked at $9.79M in Q4 2022. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Shorepoint Capital Partners held 32,205 shares of AbbVie worth $7.46M as of Q3 2025.
  • AbbVie was a new Shorepoint Capital Partners position in Q3 2025.
  • AbbVie made up 1.48% of Shorepoint Capital Partners's portfolio in Q3 2025, its #19 holding.
  • Shorepoint Capital Partners first reported a position in AbbVie in Q1 2019 and has held it in 25 quarters since.
  • Shorepoint Capital Partners's AbbVie position peaked at $9.79M in Q4 2022.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Shorepoint Capital Partners's 13F filing for Q3 2025, filed 3 Oct 2025.